Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration

Current Opinion in Ophthalmology

Volumn 24, Issue 3, 2013, Pages 190-196

  Scott, Adrienne W ^a   Bressler, Susan B ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Aflibercept; Age Related Macular Degeneration; Bevacizumab; Choroidal Neovascularization; Ranibizumab

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR;

ARTERIAL THROMBOEMBOLISM; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG SAFETY; ENDOPHTHALMITIS; EYE DISEASE; FOLLOW UP; HUMAN; LONG TERM CARE; MORBIDITY; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; TREATMENT DURATION; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84876298555     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32835fefee     Document Type: Review

References (31)

1. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1992; 99:933-943.
2. Vingerling JR, Dielemans I, Hofman A, et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 1995; 102:205-210.
3. Wong T, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration -a systematic review of the literature and meta-analysis. Ophthalmology 2008; 115:116-126.
4. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1432-1444.
5. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116: 57-65.
6. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med 2006; 355:1419-1431.
7. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3:391-400.
8. Kim H, Robinson SB, Csaky KG. FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 2009; 15:2803-2812.
9. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364:1897-1908. This study is the largest, prospective, randomized clinical trial to provide Level 1 evidence for bevacizumab use in neovascular AMD, and confirmed the noninferiority of bevacizumab monthly to both ranibizumab monthly and ranibizumab asneeded regimens for neovascular AMD. There are more reported systemic serious adverse events with bevacizumab treatment.
10. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration. One-year findings from the IVAN randomized trial. Ophthalmology 2012; 119:1399-1411. At the1-year timepoint of this study, the authors conclude that ranibizumab and bevacizumab confer equivalent visual function benefits, and although ranibizumab and continuous treatment result in better anatomic outcomes, there was no significant difference in visual function. In contrast with the CATT, in which serious systemic adverse events were higher among bevacizumab-treated participants, in IVAN, there was no difference between drugs in the proportion experiencing a serious systemic adverse event.
11. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 2012; 119:2537-2548. These study results confirmed aflibercept as an effective treatment regimen for neovascular AMD. Aflibercept given every 8 weeks, following three doses administered monthly, was found to be a noninferior treatment compared with monthly ranibizumab, with similar visual and anatomic gains attained with this aflibercept regimen after 1 year.
12. Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2012; 119:1175-1183. This open-label extension study provides long-term follow-up of ranibizumab treatment and concludes that ranibizumab treatment for at least 4 years is well tolerated. These study results also confirm that vision gains acquired after monthly ranibizumab tend to decline when patients are switched to less frequent ranibizumab regimens with less frequent follow-up.
13. Antoszyk AN, Tuomi L, Chung CY, Singh A. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008; 145:862-874.
14. Patel RD, Rominder RS, Hariprasad SM. Review of ranibizumab trials for neovascular age-related macular degeneration. Semin Ophthalmol 2011; 26:372-379.
15. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119:1388-1398. This study confirms that there is a greater mean decrease in vision in the year 2 after switching from monthly ranibizumab or bevacizumab treatment to as-needed treatment. Patients treated with monthly anti-VEGF inhibitor tended to have higher rates of incident geographic atrophy through year 2.
16. Regeneron Pharmaceuticals, Inc. Two year results of phase 3 studies with EYLEA (aflibercept) injection in wet AMD show sustained improvement in visual acuity. Available at http://investor.regeneron.com/releasedetail. cfmReleaseID629800.
17. Browning DJ, Kaiser PK, Rosenfeld PJ, et al. Aflibercept for age-related macular degeneration: a game-changer or quiet additionAm J Ophthalmol 2012; 154:222-226.
18. Silva R, Axer-Siegel R, Eldem B, et al. SECURE study: long-term safety of ranibizumab 0.5mg in neovascular age-related macular degeneration. Ophthalmology 2013; 120:130-139. This study concludes that ranibizumab given on a flexible, vision-guided dosing regimen is well tolerated over 2 years, with a low incidence of ocular or nonocular adverse events and serious adverse events.
19. Schmidt-Erfurth U, Eldem B, Guymer R, et al., EXCITE Study Group. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE Study. Ophthalmology 2011; 118:831-839.
20. Holz FG, Amoaku W, Donate J, et al., SUSTAIN Study Group. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011; 118:663-671.
21. Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011; 56:95-113.
22. Avastin (bevacizumab). Full prescribing information. Genentech, Inc. 2008.
23. Kaiser PK, Cruess AF, Bogaert P, et al. Balancing risk in ophthalmic prescribing: assessing safety of anti-VEGF therapies and the risks associated with unlicensed medicines. Graefes Arch Clin Exp Ophthalmol 2012; 250:1563-1571.
24. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005; 69 (Suppl. 3):25-33.
25. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99:1232-1239.
26. Food and Drug Administration. 15 October 2012. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHuman MedicalProducts/ucm323946.htm. [Accessed 28 December 2012].
27. Goldberg RA, Flynn HW Jr., Isom RF, et al. An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol 2012; 15:204-208. This study highlights the potential for devastating visual consequences following the intraocular use of improperly compounded bevacizumab.
28. Mitchell P, Annemans L, White R, et al. Cost effectiveness of treatments for wet age-related macular degeneration. Pharmacoeconomics 2011; 29:107-131.
29. United States Senate Special Committee on Aging. Statement of Jonathan Blum, Deputy Administrator andDirector,Center forMedicare and Medicaid Services, on sustaining the Medicare program through lower costs, before the United States Senate Special Committee on Aging. 21 July 2011. Available at http://aging.senate.gov/events/hr236jb.pdf. [Accessed 28 December 2012].
30. Davis J, Olsen TW, Steward M, Sternberg P. How the comparison of agerelated macular degeneration treatments trial results will impact clinical careAm J Ophthalmol 2011; 152:509-514.
31. Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or toleranceBr J Ophthalmol 2012; 96:1-2.